| 11807600 |
Synthesis of novel ketone body analogs for use as a nutritional supplement |
Samuel J. Rozzoni |
2023-11-07 |
|
| 9487505 |
Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
Wilfried Lubisch, Wilfried Hornberger, Thorsten Oost, Liliane Unger, Wolfgang Wernet +1 more |
2016-11-08 |
$206,870,000 |
| 9242933 |
Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) |
Hervé Geneste, Wilfried Braje, Wilhelm Amberg, Mario Mezler, Margaretha Henrica Maria Bakker |
2016-01-26 |
$303,602,000 |
| 8895749 |
4-(4-pyridinyl)-benzamides and their use as rock activity modulators |
Helmut Mack, Nicole Teusch, Bernhard Muller, Wilfried Hornberger, Michael Jarvis +5 more |
2014-11-25 |
$105,847,000 |
| 8580842 |
Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
Wilfried Lubisch, Wilfried Hornberger, Thorsten Oost, Liliane Unger, Wolfgang Wernet +1 more |
2013-11-12 |
$21,493,000 |
| 8476275 |
N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine D3 receptor |
Wilfried Braje, Andreas Haupt, Wilfried Lubisch, Roland Grandel, Karla Drescher +3 more |
2013-07-02 |
$21,808,000 |
| 8445686 |
4-(4-pyridinyl)-benzamides and their use as rock activity modulators |
Helmut Mack, Nicole Teusch, Bernhard Mueller, Wilfried Hornberger, Michael Jarvis +5 more |
2013-05-21 |
$233,289,000 |
| 8350055 |
Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
Thorsten Oost, Wilfried Hornberger, Hervé Geneste, Wolfgang Wernet, Liliane Unger +1 more |
2013-01-08 |
$26,270,000 |
| 8207160 |
Tetrahydrobenzazepines and their use in he modulation of the dopamine D3 receptor |
Wilfried Braje, Andreas Haupt, Wilfried Lubisch, Roland Grandel, Karla Drescher +2 more |
2012-06-26 |
$54,448,000 |
| 8183250 |
Potent PARP inhibitors |
Thomas D. Penning, Sheela A. Thomas, Philip J. Hajduk, Kathy Sarris, Vincent L. Giranda |
2012-05-22 |
$30,274,000 |
| 8114875 |
Substituted N-heterocyclic compounds and their use as dopamine D3 receptor ligands |
Hervé Geneste |
2012-02-14 |
$29,968,000 |
| 7910742 |
Survivin inhibitors |
Michael D. Wendt, Chaohong Sun, Steven W. Elmore, Aaron R. Kunzer |
2011-03-22 |
$26,839,000 |
| 7902379 |
Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
Wilfried Lubisch, Wilfried Hornberger, Thorsten Oost, Liliane Unger, Wolfgang Wernet +1 more |
2011-03-08 |
$24,368,000 |
| 7592466 |
Ureas having antiangiogenic activity |
Fortuna Haviv, Michael Bradley |
2009-09-22 |
$133,275,000 |
| 7320979 |
N-[(piperazinyl)hetaryl]arylsulfonamide compounds |
Wilfried Braje, Andreas Haupt, Wilfried Lubisch, Roland Grandel, Karla Drescher +3 more |
2008-01-22 |
$112,270,000 |
| 6495562 |
Naphthamidine urokinase inhibitors |
Milan Bruncko, Christopher R. Dalton, Vincent L. Giranda, Jianchun Gong, Willian J. McClellan +3 more |
2002-12-17 |
$55,981,000 |
| 6387885 |
3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists |
Christopher R. Dalton, Milan Bruncko, Michele A. Kaminski, Lisa M. Frey, Fortuna Haviv |
2002-05-14 |
$75,315,000 |
| 6020521 |
Macrolide LHRH antagonists |
John T. Randolph, Fortuna Haviv, Philip Waid, Charles J. Nichols, Nicholas A. Mort +2 more |
2000-02-01 |
$89,588,000 |
| 5972898 |
3',3-N-bis-substituted macrolide LHRH antagonists |
Fortuna Haviv, John T. Randolph, Nicholas A. Mort, Christopher R. Dalton, Milan Bruncko +4 more |
1999-10-26 |
$74,678,000 |
| 5955440 |
Macrolide LHRH antagonists |
Fortuna Haviv, John T. Randolph, Nicholas A. Mort, Christopher R. Dalton, Milan Bruncko +4 more |
1999-09-21 |
$61,755,000 |
| 5508383 |
Cyclic peptide LHRH antagonists |
Fortuna Haviv |
1996-04-16 |
|
| 5491217 |
LHRH antagonists having modified aminoacyl residues at positions 5 and 6 |
Fortuna Haviv, Jonathan Greer, Rolf E. Swenson |
1996-02-13 |
|
